【开拓药业-B(09939.HK):KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组】开拓药业-B(09939.HK)公布,公司自主研发、潜在同类首创的 KX-826 酊 1.0%治疗中国成年男性雄激素脱发的关键性临床试验已于近日顺利完成 III 期阶段首例受试者入组。

金融界
30 Dec 2024
开拓药业-B(09939.HK)公布,公司自主研发、潜在同类首创的 KX-826 酊 1.0%治疗中国成年男性雄激素脱发的关键性临床试验已于近日顺利完成 III 期阶段首例受试者入组。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10